SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

02 1 2024 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

13 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

06 11 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming November Investor Conferences

01 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

01 11 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference

20 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

06 9 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

10 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

03 8 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

31 7 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 6 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

14 6 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 5 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

11 5 2023 16:05:01 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

04 5 2023 08:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conference

26 4 2023 08:05:00 提供 Nasdaq GlobeNewswire